{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:02:16Z","timestamp":1781326936207,"version":"3.54.1"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T00:00:00Z","timestamp":1322006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study compared the efficacy of a cinacalcet\u2010based regimen with unrestricted conventional therapy (vitamin D and phosphate binders) for achieving Kidney Disease Outcome Quality Initiative (K\/DOQI) targets for dialysis patients. In this multicenter, prospective study, hemodialysis patients with poorly controlled secondary hyperparathyroidism (SHPT) were randomized to receive a cinacalcet\u2010based regimen (<jats:italic>n<\/jats:italic>\u2003=\u200355) or a conventional therapy (<jats:italic>n<\/jats:italic>\u2003=\u200327). Doses of cinacalcet, vitamin D sterols, and phosphate binders were adjusted during a 12\u2010week dose\u2010titration phase to achieve intact parathyroid hormone (iPTH) levels\u2003\u2264\u200331.8\u2003pmol\/L. The primary end point was the percentage of patients with values in this range during a 24\u2010week efficacy\u2010assessment phase. The clinical response to 36\u2010week cinacalcet treatment was evaluated. A dual energy X\u2010ray absorptiometry was performed before and after 36\u2003weeks of cinacalcet therapy. Fifty\u2010eight percent of the cinacalcet group reached the primary end point, as compared with 19% of the conventional therapy group (<jats:italic>P<\/jats:italic>\u2003=\u20030.001). A higher percentage of patients receiving the cinacalcet\u2010based regimen versus conventional therapy achieved the targets for calcium, phosphorus and Ca\u2003\u00d7\u2003P. Achievement of targets was greatest in patients with less severe disease (intact PTH range, 31.8 to 53\u2003pmol\/L). Cinacalcet therapy increased proximal femur bone mineral density (BMD), but did not affect the lumbar spine. Itching intensity decreased significantly. Cinacalcet based treatment facilitates achievement of the K\/DOQI targets for iPTH and bone mineral metabolism compared with conventional therapy in hemodialysis patients. Suppression of iPTH with cinacalcet reverses bone loss in the proximal femur. Cinacalcet alleviated itching.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2011.00994.x","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T11:00:32Z","timestamp":1322046032000},"page":"547-555","source":"Crossref","is-referenced-by-count":31,"title":["Cinacalcet Hydrochloride Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients"],"prefix":"10.1111","volume":"15","author":[{"given":"Eid M","family":"El\u2010Shafey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali E","family":"Alsahow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alsaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Atia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1081\/JDI-120022551"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca \u00d7 PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh SK","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.63.s85.26.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00185.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00111-2"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1052"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FMJ04007X6"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004060512"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2000.108117"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)01103-5"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP68010"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03591006"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00870805"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V971225"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh829"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000317935"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00596.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67103.x"},{"key":"e_1_2_6_22_2","first-page":"99","article-title":"The calcimimetic compound, cinacalcet HCl, ameliorates osteitis fibrosa in rats with chronic renal insufficiency","volume":"18","author":"Wada M","year":"2003","journal-title":"J Bone Miner Res"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67139.x"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2011.00994.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2011.00994.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T06:32:48Z","timestamp":1697265168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2011.00994.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,23]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1111\/j.1744-9987.2011.00994.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2011.00994.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,23]]}}}